Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents

Journal of the American Academy of Dermatology

Volumn 46, Issue 4, 2002, Pages 495-504

  Eichenfield, Lawrence F ^a   Lucky, Anne W ^b   Boguniewicz, Mark ^c   Langley, Richard G B ^d   Cherill, Robert ^e   Marshall, Katharine ^e   Bush, Christopher ^e   Graeber, Michael ^e  

^a RADY CHILDREN'S HOSPITAL   (United States)

^b Dermatology Research Associates   (United States)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^d QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PIMECROLIMUS;

ADOLESCENT; ARTICLE; ATOPIC DERMATITIS; BURN; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ECZEMA; FEMALE; HAND DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN ALLERGY; SKIN INFLAMMATION; SKIN IRRITATION; TREATMENT OUTCOME; TREATMENT PLANNING; UPPER RESPIRATORY TRACT INFECTION;

EID: 0036553479     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2002.122187     Document Type: Article

References (31)

1. Larsen FS, Holm NV, Henningsen K. Atopic dermatitis: a genetic-epidemiologic study in a population-based twin sample. J Am Acad Dermatol 1986;15:487-94.
2. Williams H, Robertson C, Stewart A, Ait-Khaled N, Anabwani G, Anderson R, et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol 1999;103:125-38.
3. Laughter D, Istvan JA, Tofte SJ, Hanifin JM. The prevalence of atopic dermatitis in Oregon schoolchildren. J Am Acad Dermatol 2000;43:649-55.
4. Rajka G. Natural history and clinical manifestations of atopic dermatitis. Clin Rev Allergy 1986;43-26.
5. Hanifin JM, Chan S. Biochemical and immunologic mechanisms in atopic dermatitis: new targets for emerging therapies. J Am Acad Dermatol 1999;41:72-7.
6. Leung DYM. Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 2000;105: 860-76.
7. Leung DY, Hanifin JM, Charlesworth EN, Li JT, Bernstein IL, Berger WE, et al. Disease management of atopic dermatitis: a practice parameter. Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. Work Group on Atopic Dermatitis. Ann Allergy Asthma Immunol 1997;79: 197-211.
8. Boguniewicz M, Leung DYM. New concepts in atopic dermatitis. Compr Ther 1996;22:144-51.
9. Meingassner JG, Grassberger M, Fahrngruber H, Moore HD, Schuurman H, Stuetz A. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 1997;137:568-76.
10. Atakan N, Erdem C. The efficacy, tolerability and safety of a new oral formulation of Sandimmun-Sandimmun Neoral in severe refractory atopic dermatitis. J Eur Acad Dermatol Venereol 1998;11:240-6.
11. Ruzicka T, Bieber T, Schopf E, Rubins A, Dobozy A, Bos JD, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997;337:816-21.
12. Reitamo S, Wollenberg A, Schopf E, Perrot JL, Marks R, Ruzicka T, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol 2000;136:999-1006.
13. Paller A, Eichenfield LF, Leung DY, Stewart D, Appell M. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001;44: 547-57.
14. Rappersberger K, Komar M, Ebelin ME, Scott G, Bueche M, Burtin P, et al. Oral SDZ ASM 981: safety, pharmacokinetics and efficacy in patients with moderate to severe chronic plaque psoriasis. Presented at the 61st Annual Meeting of the Society for Investigative Dermatology, Chicago, Ill, May 10-14, 2000. J Invest Dermatol 2000;114(Suppl 4):Abstract 149.
15. Mrowietz U, Graeber M, Brautigam M, Thurston M, Wagenaar A, Weidinger G, et al. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 1998;139:992-6.
16. Neckermann G, Bavandi A, Meingassner JG. Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981. Br J Dermatol 2000;142:669-79.
17. Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999;141:264-73.
18. van Leent EJ, Graber M, Thurston M, Wagenaar A, Spuls PI, Bos JD. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998;134:805-9.
19. Allen R, Davies T, Bos JD, Van Leent EJM, Harper J, Green A, et al. Pharmacokinetics of SDZ ASM 981 Cream 1% in adults and children. Presented at the October 2000 meeting of the European Academy of Dermatology and Venereology, Geneva, Switzerland [abstract]. J Eur Acad Dermatol Venereol 2000; 14:523-5.
20. Williams HC, Burney PG, Pembroke AC, Hay RJ. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. Ill. Independent hospital validation. Br J Dermatol 1994;131:406-16.
21. Hanifin JM, Thurston MS, Omoto M, Cherill RJ, Tofte SJ, Graeber M, et al. The eczema area and severity index (EASI). Assessment of reliability in atopic dermatitis. Exp Dermatol 2001;10:11-8.
22. Rudikoff D, Lebwohl D. Atopic dermatitis. Lancet 1998;351: 1715-21.
23. Woodmansee D, Christiansen S. Atopic dermatitis. Pediatr Ann 1998;27:710-6.
24. Meingassner JG, Hiestand P, Bigout M, Grassberger M, Schuurman H, Tanner M, et al. SDZ ASM 981 is highly effective in animal models of skin inflammation, but has only low activity in models indicating immunosuppressive potential [abstract]. J Invest Dermatol 2001;117:532.
25. Queille-Roussel C, Paul C, Duteil L, Lefebvre MC, Rapatz G, Zagula M, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001;144:507-13.
26. van der Heijden FL, Wieranga EA, Bos JD, Kapsenberg ML. High frequency of IL-4-producing CD4+ allergen-specific T lymphocytes in atopic dermatitis lesional skin. J Invest Dermatol 1991;97:389-94.
27. Hamid Q, Naseer T, Minshall EM, Song YL, Boguniewicz M, Leung DY. In vivo expression of IL-12 and IL-13 in atopic dermatitis. J Allergy Clin Immunol 1996;98:225-31.
28. Goto T, Kino T, Hatanaka H, Okuhara M, Kohsaka M, Aoki H, et al. FK 506: historical perspectives. Transplant Proc 1991;23:2713-17.
29. Harper JI, Ahmed I, Barclay G, Lacour M, Hoeger P, Cork MJ, et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol 2000;142:52-8.
30. Groisser DS, Griffiths CE, Ellis CN, Voorhees JJ. A review and update of the clinical uses of cyclosporine in dermatology. Dermatol Clin 1991;9:805-17.
31. Meingassner J, Fahrngruber H, Bavandi A. SDZ ASM 981, in contrast to CyA and FK 506, does not suppress the primary immune response in murine allergic contact dermatitis. J Invest Dermatol 2000;114:832.